ThermoGenesis Releases Enhanced X-MINI CD3 Selection Kit For Researchers.
RANCHO CORDOVA, Calif, April 17, 2019 -- ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (NASDAQ: KOOL), announced the release of the enhanced X-MINI CD3 Selection Kit for the research market.
The kit expands on the ability of the original X-MINIkit to select the CD3+ target cells from prepared mononuclear cell samples or from a sample of whole blood.
The kit is the first in a planned product line that will enable the selection of numerous other cell types needed for a variety of applications.
Also included with the release is the X-MINI Pressor accessory, used in conjunction with the X-MINI selection kits to eliminate the X-BACS reagent's buoyancy during the final processing steps.
According to the company, there is an increasing need within the cell-based therapeutics market for cutting-edge tools that improve the manufacturing process, allowing development of the highest-quality therapies, including CAR-T.
The company says it will release additional cell selection kits during 2019, as expansions of its X-BACS product line.
The X-MINI Pressor enables X-MINI kit users to simplify their workflows by improving consistency and decreasing the number of repetitive, manual processing steps required.
The X-MINI Selection Kits leverage the company's proprietary X-BACS platform to provide tangible advantages over traditional cell selection technologies through a unique combination of attributes, including ease of use, high cell recovery and reproducibility and minimal cost.
Both the newly enhanced X-MINI CD3 Selection Kit and X-MINI Pressor are available for purchase.